UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000038441 |
|---|---|
| Receipt number | R000043798 |
| Scientific Title | Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14 |
| Date of disclosure of the study information | 2019/11/01 |
| Last modified on | 2020/10/15 14:53:52 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14
Acronym
Absorption study of SNR14
Scientific Title
Plasma concentration and urinary excretion of SNR14 in healthy male volunteers after single oral administration of foods containing SNR14
Scientific Title:Acronym
Absorption study of SNR14
Region
| Japan |
Condition
Condition
Healthy Volunteer
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To examine the absorption of SNR14 after single oral administration of foods containing SNR14
Basic objectives2
Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Plasma concentration of SNR14 after single oral administration
Key secondary outcomes
Urinary excretion of SNR14 after single oral administration
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Open -no one is blinded
Control
Dose comparison
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Single oral administration of SNR14 A
Interventions/Control_2
Single oral administration of SNR14 B
Interventions/Control_3
Single oral administration of SNR14 C
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 60 | years-old | >= |
Gender
Male
Key inclusion criteria
1)Subjects who are voluntarily giving written informed consent.
2)Healthy males aged between 20 and 60.
3)Subjects who can eat test foods.
4)Subjects who can take meals, eat test foods, take blood samples, take urine samples and stay quiet and rest on the schedule indicated by investigators.
Key exclusion criteria
1)Subjects whose clinical inspection results are outside of the normal range and who are estimated inappropriate to this study.
2)Subjects who have or had disorder in digestive, circulatory or endocrine system and who are estimated inappropriate to this study.
3)Subjects who take medicines for treatment of diseases.
4)Subjects who have allergy.
5)Subjects who are estimated inappropriate to this study by principal investigator or investigators.
Target sample size
12
Research contact person
Name of lead principal investigator
| 1st name | Yasutaka |
| Middle name | |
| Last name | Ikeda |
Organization
Otsuka Pharmaceutical Co., Ltd.
Division name
Saga Nutraceuticals Research Institute
Zip code
842-0195
Address
5006-5 Aza Higashiyama, Omagari, Yoshinogari-cho Kanzakigun, Saga
TEL
0952-52-1522
Ikeda.Yasutaka@otsuka.jp
Public contact
Name of contact person
| 1st name | Minoru |
| Middle name | |
| Last name | Akiyama |
Organization
Otsuka Pharmaceutical Co., Ltd.
Division name
Saga Nutraceuticals Research Institute
Zip code
842-0195
Address
5006-5 Aza Higashiyama, Omagari, Yoshinogari-cho Kanzakigun, Saga
TEL
0952-52-1522
Homepage URL
Akiyama.Minoru@otsuka.jp
Sponsor or person
Institute
Otsuka Pharmaceutical Co., Ltd.
Institute
Department
Personal name
Funding Source
Organization
Otsuka Pharmaceutical Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Otsuka Pharmaceutical Co., Ltd.
Address
Shinagawa Grand Central Tower, 2-16-4, Konan, Minato-ku, Tokyo
Tel
03-6717-1499
shimizu_se@otsuka.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 10 | Month | 09 | Day |
Date of IRB
| 2019 | Year | 10 | Month | 09 | Day |
Anticipated trial start date
| 2019 | Year | 10 | Month | 15 | Day |
Last follow-up date
| 2019 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 10 | Month | 30 | Day |
Last modified on
| 2020 | Year | 10 | Month | 15 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043798
